Navigation Links
NicOx Announces Favorable Blood Pressure Data for Naproxcinod in a Large ABPM Study
Date:11/4/2008

0.011) in favor of naproxcinod.

Michele Garufi, Chairman and CEO of NicOx, commented: "These excellent results are an important addition to the consistent data we are accumulating on naproxcinod's potentially non-detrimental blood pressure profile and its clear differentiation from naproxen. We are confident that naproxcinod's potential will be confirmed by the further clinical results expected in the coming months."

The three doses of naproxcinod showed good general safety and tolerability. In the naproxcinod arm 32 patients (54.2%) experienced one or more adverse events, compared to 38 patients (64.4%) in the naproxen arm. There were no serious adverse events in the naproxcinod arm.

Additional note on study design: The 111 study was a 12-week pharmacodynamic ABPM trial (with 9 weeks of active treatment), with a double-blind, parallel group design, in which 118 OA patients with controlled hypertension were enrolled at 30 clinical sites in the United States. Eligible patients were 40 years and older and had been suffering from osteoarthritis for at least three months, with at least one hip or knee involved. In addition to OA, all patients were diagnosed with controlled essential hypertension (i.e. SBP <140 mmHg and DBP <90 mmHg) and were treated with stable doses of up to two different classes of antihypertensive agents. Patients with uncontrolled hypertension were excluded.

NicOx (Bloomberg: COX:FP, Reuters: NCOX.PA) a product-driven biopharmaceutical company dedicated to the development and future commercialization of investigational drugs for unmet medical needs. NicOx is applying its proprietary nitric oxide-donating technology to develop an internal portfolio of New Chemical Entities (NCEs) in the therapeutic areas of inflammatory and cardio-metabolic disease.

Resources are focused on the development of naproxcinod, a proprietary NCE and the first compound in the Cyclooxygenase-Inhibiting Nitric Oxide-Donating (CINOD) class of
'/>"/>

SOURCE NicOx
Copyright©2008 PR Newswire.
All rights reserved

1082

GOOD

Page: 1 2 3 4

Related medicine technology :

1. NicOx Announces Second Naproxcinod Pivotal Phase 3 Study (302) Meets Efficacy Primary Endpoints and Supports Non-Detrimental Blood Pressure Effect
2. NicOx Announces Top-Line Results From Naproxcinod 52-Week 301 Safety Extension
3. NicOx Completes Enrollment of Two Ambulatory Blood Pressure Measurement (ABPM) Studies for Naproxcinod in Hypertensive OA Patients
4. NicOx Announces Blood Pressure Analysis From 301 Phase 3 Study for Naproxcinod at EULAR
5. NicOx Completes Patient Enrollment in Third Naproxcinod Pivotal Phase 3 Study
6. NicOx Announces Initiation of First Phase 1 Study of Investigational Nitric Oxide-Donating Agent in Hypertensive Patients by Merck & Co., Inc.
7. Financial Results for Full Year 2007: NicOx Significantly Advances Clinical Programs
8. NicOx Announces Pfizer Initiates Phase 2 Clinical Development for PF-03187207 in Japan
9. NicOx Completes Enrollment in Second Pivotal Phase 3 Study for Naproxcinod and Provides Development Update
10. NicOx Announces TOPIGEN Initiates Phase 2 Proof of Concept Study in COPD for TPI 1020
11. NicOx Naproxcinod Phase 3 Results Presented at American College of Rheumatology
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/30/2014)... NEW YORK , Sept. 30, 2014 ... stage. Growing ageing population and rise in the incidence ... of chronic wounds and in affordability of better quality ... Chinese wound care market. Universal coverage of public health ... products would further stimulate demand. Based on the findings ...
(Date:9/30/2014)... 30, 2014  Based on its recent analysis ... Sullivan recognizes Ventana Medical Systems, Inc. (Ventana), a ... North American Frost & Sullivan Award for Technology ... with a focus on innovation and improving patient ... tissue-based cancer diagnostic solutions for patients worldwide. ...
(Date:9/30/2014)... Passport Health, one of the largest immunizers ... FluFree.com, a website designed to promote, educate about, and ... years, Passport Health has provided its clients with protection ... FluFree.com is designed to address the growing gap between ... who actually chose to get vaccinated. "We ...
Breaking Medicine Technology:China Wound Care Market 2China Wound Care Market 3Frost & Sullivan applauds the diversity of Ventana products and services for the cancer diagnostics market 2Frost & Sullivan applauds the diversity of Ventana products and services for the cancer diagnostics market 3Frost & Sullivan applauds the diversity of Ventana products and services for the cancer diagnostics market 4Passport Health Launches FluFree.com - Aims To Improve Flu Vaccination Rates and Fulfill Growing Public Health Priority 2Passport Health Launches FluFree.com - Aims To Improve Flu Vaccination Rates and Fulfill Growing Public Health Priority 3
... WIRE)--May 10, 2007 - An evaluation of the,safety ... the,treatment of vaginal atrophy, a frequent complaint of,postmenopausal ... American,Menopause Society (NAMS). Entitled "The role of local ... women:,2007 position statement of The North American Menopause ...
... Technology Demonstrates Novel,Anti-Inflammatory Properties, New Surfaxin ... Academic,Societies Annual Meeting , WARRINGTON, Pa., ... Discovery,Laboratories, Inc. (Nasdaq:DSCO) announced that new ... novel KL-4 surfactant,(lucinactant) replacement technology were ...
Cached Medicine Technology:New Position Statement from The North American Menopause Society,Addresses Use of Local Estrogen for Treatment of Vaginal Atrophy in,Postmenopausal Women 2New Position Statement from The North American Menopause Society,Addresses Use of Local Estrogen for Treatment of Vaginal Atrophy in,Postmenopausal Women 3Discovery's KL-4 Surfactant Technology Demonstrates Novel,Anti-Inflammatory Properties 2Discovery's KL-4 Surfactant Technology Demonstrates Novel,Anti-Inflammatory Properties 3Discovery's KL-4 Surfactant Technology Demonstrates Novel,Anti-Inflammatory Properties 4Discovery's KL-4 Surfactant Technology Demonstrates Novel,Anti-Inflammatory Properties 5Discovery's KL-4 Surfactant Technology Demonstrates Novel,Anti-Inflammatory Properties 6
(Date:9/30/2014)... (PRWEB) September 30, 2014 Fat Burning ... specialist and best-selling author Mike Geary that is helping people ... their body into a fat-burning machine in less than 24 ... investigative review. , “In our culture that is becoming ... hard to decipher what is really fact and fiction when ...
(Date:9/30/2014)... (PRWEB) September 30, 2014 VisitandCare.com ... in Turkey has gone up more than 79 percent ... medical tourism company also reported total revenue tripled for ... , The company’s professional strategy has allowed them to ... ultimately designed for patient comfort and privacy — with ...
(Date:9/30/2014)... With the flu season upon ... day, it’s a perfect time to announce Jan-Pro’s ... is an electro-static disinfectant delivery system that dries ... missed with spray-on disinfectant applicators. , The EnviroShield ... electrostatic negative charge to the disinfecting solution. ...
(Date:9/30/2014)... 30, 2014 Dr. Karl R.O.S. Johnson, ... program of care that is dramatically improving the ... clinic—Johnson Chiropractic Neurology & Nutrition—applies a proprietary, multi-dimensional approach ... also addresses sources of inflammation, neurology of the joint ... chain” from the brain to the spine, to the ...
(Date:9/30/2014)... 30, 2014 (HealthDay News) -- Medicare should cover low-dose ... risk for the disease, a coalition of more than ... which includes the Lung Cancer Alliance, the Society of ... Cancer Society and the American Society of Clinical Oncology, ... the U.S. Centers for Medicare & Medicaid Services (CMS). ...
Breaking Medicine News(10 mins):Health News:Fat Burning Kitchen: Review Exposes Mike Geary’s 24-Hour Diet Transformation for Helping the Body Burn Fat Through a Natural Diet 2Health News:Fat Burning Kitchen: Review Exposes Mike Geary’s 24-Hour Diet Transformation for Helping the Body Burn Fat Through a Natural Diet 3Health News:VisitandCare.com Announces Record Demand for Plastic Surgery in Turkey 2Health News:VisitandCare.com Announces Record Demand for Plastic Surgery in Turkey 3Health News:VisitandCare.com Announces Record Demand for Plastic Surgery in Turkey 4Health News:Columbus Janitorial Company Announces New Disinfecting System for your workplace 2Health News:Newly Developed Program Eases Chronic Knee Pain without Surgery and in as Little as Two Days 2Health News:Newly Developed Program Eases Chronic Knee Pain without Surgery and in as Little as Two Days 3Health News:Groups Call for Medicare Coverage of Lung Cancer Screening 2
... be attributed to Jeff Smith, DVM, president, ... California Veterinary Medical Association:, SACRAMENTO, Calif., Oct. 15 ... a disappointment. The decision,of the Court of Appeals -- which ... the delivery of veterinary services in,California. The regulatory authority of ...
... the knowledge and treatment of schizophrenia, depression, ... Oct. 15 Five of the most prestigious ... of great,achievement by NARSAD, the world,s leading charity ... here this Friday at the,Waldorf-Astoria Hotel. Because ...
... for patients, researchers say , , MONDAY, Oct. 15 ... find nicotine patches or hot pepper-based chemicals on ... patches and the hot pepper-derivative capsaicin both provided ... presented at the American Society of Anesthesiologists, annual ...
... as a pivotal tumor suppressor for both human and mouse ... The research, published by Cell Press in the October 2007 ... of new drug therapies for lung cancer. , Lung cancer ... responsible for 1.3 million deaths each year. Non-small-cell lung cancers ...
... ALBUQUERQUE, N.M., Oct. 15 Two clinical,research scientists ... ( http://www.biomoda.com ) of Albuquerque, NM, to assist ... detection,testing and other cancer diagnostic technology. "Constance ... diagnostic products development and FDA regulations to,Biomoda. She ...
... 15 HMS Holdings Corp. (Nasdaq:,HMSY) today announced it will host a webcast ... the financial results for the,third quarter 2007, which ended September 30. Financial results ... Robert Holster, Chairman and CEO, WHEN: ... 10:00 AM ET, HOW: Presentation: ...
Cached Medicine News:Health News:California Veterinary Medical Association Reacts to Supreme Court Decision 2Health News:NARSAD - the World's Leading Mental Health Research Charity - Presents 2007 Prizes for Outstanding Psychiatric Research at New York Gala, October 19th 2Health News:NARSAD - the World's Leading Mental Health Research Charity - Presents 2007 Prizes for Outstanding Psychiatric Research at New York Gala, October 19th 3Health News:Nicotine, Chili Peppers Offer Post-Surgery Pain Relief 2Health News:Nicotine, Chili Peppers Offer Post-Surgery Pain Relief 3Health News:DMP1 deletion cooperates with oncogenic K-ras in lung cancer 2Health News:Two Scientists Join Team of Biomoda, Inc. 2Health News:HMS Holdings Corp. Hosts Third Quarter 2007 Financial Teleconference and Presentation 2
... Access ...unlike any trocar system you've ever ... actually four systems in one designed ... adaptive to all of your needs., ... or dilating tip styles, OnePort™ can effectively ...
... complete line of Surgical Access ...unlike any ... OnePort™ trocar system is actually four systems ... operationally flexible and clinically adaptive to all ... in disposability and bladed or dilating tip ...
... FPK01 Thoracic Trocar Pak ... 15mm flexible sleeves and (1) ... ,FPK02 Thoracic Trocar Pak ... 15mm flexible sleeves., ,FPK03 ...
... FLEXIPATH Flexible Surgical Thoracic Trocar ... mechanical obturator and a flexible ... prevent puncture or laceration to ... has securing holes to secure ...
Medicine Products: